Custom Search


Thursday 17 August 2006

Rheumatoid Arthritis

By: Yahoo News

This study will evaluate the effectiveness of retreatment with rituximab in people with active rheumatoid arthritis (RA) who are receiving methotrexate (MTX) and who have had an inadequate response to tumor necrosis factor (TNF) inhibitors.

Volunteers 18-80 may be included who have been diagnosed with RA for at least six months, are receiving outpatient treatment, and have been using MTX 10-25 mg per week for at least 12 weeks. Patients may not participate who have rheumatic autoimmune disease other than RA, a diagnosis of juvenile idiopathic arthritis (JIA), juvenile rheumatoid arthritis (JRA), or RA before age 16.

The research site is in Virginia Beach, Va.

More information

Please see

Read Original Text

Use of this site is subject to the following terms of use